AllSci News
Enveric secures US patent for non-hallucinogenic psilocybin derivatives treating psychiatric disorders
Enveric Biosciences (Nasdaq: ENVB), headquartered in Cambridge, Massachusetts, announced receipt of US Patent No. 12,605,361 from the USPTO on April 21, 2026,…
Bayer’s asundexian Factor XIa inhibitor receives FDA Priority Review for secondary stroke prevention
Bayer (XETRA: BAYN) announced that the US FDA has accepted its New Drug Application (NDA) and granted Priority Review designation for asundexian…
Gossamer Bio exchanges USD 120m convertible debt to stabilize balance sheet ahead of seralutinib PAH filing
San Diego-based Gossamer Bio (Nasdaq: GOSS) has announced an exchange offer and concurrent consent solicitation targeting more than USD 120 million of its...
Hansa Biopharma licenses Europe, MENA rights for Idefirix to SERB Pharmaceuticals for EUR 115m
Hansa Biopharma (Nasdaq Stockholm: HNSA), the Lund, Sweden-based biopharmaceutical company, has licensed European and MENA commercialization rights for...
ImmunityBio secures five US patents for ANKTIVA plus BCG bladder cancer therapy through 2035
ImmunityBio (Nasdaq: IBRX), headquartered in Culver City, California, has received five issued US patents covering the combination of its IL-15 receptor agonist…
Nanobiotix's JNJ-1900 produces strong early Phase II data in stage III lung cancer
Nanobiotix (Euronext: NANO; Nasdaq: NBTX) reported an 85.7% overall response rate and a 57.1% complete response rate in seven patients with stage III...
Ipsen hopeful for corabotase as Botox alternative after positive Phase II
Ipsen (Euronext: IPN; ADR: IPSEY) reported Phase II data for corabotase in moderate-to-severe glabellar lines showing that 60.8% of patients maintained a...
Novartis posts data for Pluvicto in indication-expanding prostate cancer trial
Novartis (SWX: NOVN) reported new data from the Phase III PSMAddition trial showing that lutetium (177Lu) vipivotide tetraxetan (Pluvicto) reduced the risk...
FDA approves first interchangeable Simponi biosimilars
The US FDA has approved Immgolis and Immgolis Intri (golimumab-sldi) as the first interchangeable biosimilars to Johnson & Johnson’s Simponi and Simponi…
Canadian researchers identify naporafenib-trametinib combo strategy for anaplastic thyroid cancer
Researchers at Western University and London Health Sciences Centre in London, Ontario, Canada, working with collaborators at the Ontario Institute for...
Quince acquires Orphai for inhaled mTOR inhibitor, raises USD 187m
Quince Therapeutics (Nasdaq: QNCX), based in South San Francisco, has acquired Orphai Therapeutics Inc., a private clinical-stage company, in a...
Merck partners with China's Degron, Medimscience on molecular glue, autoimmune programs
Merck (NYSE: MRK) has signed two clinical collaboration agreements and two memorandums of understanding with Chinese biotech companies through its MSD R&D...
Context Therapeutics pays USD 6.5m to buy out BioAtla CT-202 Nectin-4 CD3 obligations
Context Therapeutics (Nasdaq: CNTX) has paid USD 6.5 million to buy out all future milestone and royalty obligations on CT-202, its Nectin-4 x CD3 T cell...
Neurocrine completes USD 2.9b acquisition of Soleno for rare disease portfolio expansion
Neurocrine Biosciences (Nasdaq: NBIX) has completed its acquisition of Soleno Therapeutics for a total equity value of USD 2.9 billion, adding VYKAT XR...
BioMarin faces uncertainty for ENPP1 enzyme replacement therapy after mixed Phase III
BioMarin Pharmaceutical (Nasdaq: BMRN) reported that its Phase III ENERGY 3 trial evaluating BMN 401 in children aged 1 to 12 with ENPP1 deficiency met only...
The AllSci Brief
Free, systematic R&D and deal news. Daily.